Abstract #0847

Assessing Glutaminase Inhibition Treatment Response in Ovarian Cancer by Hyperpolarized Magnetic Resonance Spectroscopy

Prasanta Dutta¹, Deanna Glassman², Mark Kim², Meredith L Spradlin³, Emine Bayraktar², Elaine Stur², Selanere Mangala², Katherine Foster², Sanghoon Lee², Timothy A Yap⁴, Shannon Westin², Livia Eberlin⁵, Anil K Sood², and Pratip Bhattacharya¹

¹Cancer Systems Imaging, UT-MD Anderson Cancer Center, Houston, TX, United States, ²Gynecologic Oncology and Reproductive Medicine, UT-MD Anderson Cancer Center, Houston, TX, United States, ³Chemistry, UT- Austin, Austin, TX, United States, ⁴Investigational Cancer Therapeutics, UT-MD Anderson Cancer Center, Houston, TX, United States, ⁵Surgery, Baylor College of Medicine, Houston, TX, United States

Synopsis

Keywords: Hyperpolarized MR (Non-Gas), Metabolism, Metabolic Imaging

The metabolic vulnerability of anti-VEGF antibody (AVA) resistant ovarian cancer with glutaminase inhibitor (GLSi) therapy was assessed by hyperpolarized ¹³C-pyruvate magnetic resonance spectroscopy (HP-MRS) in vivo and by desorption electrospray ionization spectroscopic (DESI-MS) imaging ex vivo. The lactate-to-pyruvate ratio was used as the treatment response imaging biomarker.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.